Ambu has been facing headwinds on the stock exchange in recent days, and Head of Equity Research at Carnegie Investment Bank Niels Granholm-Leth has identified several potential factors as to why.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Sonova completes Hysound Group acquisition, strengthens presence in China
The hearing aid giant now owns over 200 hearing clinics in China.
Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
FDA confirms rejection of Y-mabs' cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Top news from MedWatch this week
Miss anything?
Acquisitions to help Coloplast attain growth goal
Coloplast aims to grow by 10%, and chairman of the board Lars Rasmussen thinks this will be realized through multiple acquisitions.
Director, QA Commercial Drug Substance, Ascendis Pharma 
QA Specialist 
Principal Systems Engineer 
Laboratory assistants for an exciting QC department 
Supply Chain Manager 
Head of Engineering 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Nordic Medical Manager, Central Nervous System 
Chief consultant for Dansk Erhvervs Health and life science 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market 
(Senior) CMC Project Manager